IDH2 and acute myeloid leukemia: Similarly, an enasidenib–AZA combination in unfit newly diagnosed AML (phase 1b/2 AG221-AML-005) resulted in greater IDH2 mutation reduction; the median VAF was 0.023% in CR vs. 0.233% in CRi/CRp/PR/MLFS vs. 0.872% in no response [89].